ret Receptor tyrosine kinase immunoreactivity is altered in glial cell line-derived neurotrophic factor-responsive neurons following lesions of the nigrostriatal and septohippocampal pathways

Neuroscience

Volumn 80, Issue 1, 1997, Pages 9-16

  Araujo, D M ^a,b   Hilt, D C ^a   Miller, P J ^a   Wen, D ^a   Jiao, S ^a   Lapchak, P A ^a  

^a AMGEN INC   (United States)

^b NONE   (United States)

Author keywords

Alzheimer's disease; Cholinergic; Dopaminergic; Huntington's disease; Parkinson's disease; Proto oncogene

Indexed keywords

CELL SURFACE RECEPTOR; CHOLINE ACETYLTRANSFERASE; DOPAMINE; EXCITOTOXIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; NERVE GROWTH FACTOR RECEPTOR; OXIDOPAMINE; PROTEIN TYROSINE KINASE; QUINOLINIC ACID; TIAGABINE; TYROSINE 3 MONOOXYGENASE;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL DEATH; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; GENE MUTATION; GLIA CELL; HIPPOCAMPUS; HUNTINGTON CHOREA; IMMUNOREACTIVITY; MOUSE; NERVE FIBER TRANSECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTECTION; PROTO ONCOGENE; RAT; SUBSTANTIA NIGRA;

EID: 0030863650     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)00122-X     Document Type: Letter

References (36)

1. Albin R. L., Young A. B. and Penney J. B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-374.
2. Amaral D. G. and Witter M. P. (1995) Hippocampal Formation. In The Rat Nervous System (ed. Paxinos G.), pp. 579-628, Academic Press Inc., San Diego.
3. Araujo D. M. and Hilt D. C. (1997) Glial cell line-derived neurotrophic factor (GDNF) attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease. Neuroscience, (in press).
4. Araujo D. M., Lapchak P. A. and Hefti F. (1993) Effects of chronic basic fibroblast growth factor administration to rats with partial fimbrial transections on presynaptic cholinergic parameters and muscarinic receptors in the hippocampus: comparison with nerve growth factor. J. Neurochem. 61, 899-910.
5. Araujo D. M., Lapchak P. A., Robitaille Y., Gauthier S. and Quirion R. (1988) Differential alteration of various cholinergic markers in cortical and subcortical regions of the human brain in Alzheimer's disease. J. Neurochem. 50, 1914-1923.
6. Bowenkamp K. E., David D., Lapchak P. A., Henry M. A., Granholm A.-C., Hoffer B. J. and Mahalik T. J. (1996) 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat - A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Expl Brain Res. 111, 1-7.
7. DiFiglia M. (1990) Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci. 13, 286-289.
8. Durbec P., Marcos-Gutierrez C. V., Kilkenny C., Grigoriou M., Wartiowaara K., Suvanto P., Smith D., Ponder B., Costantini F., Saarma M., Sariola H. and Pachnis V. (1996) GDNF signalling through the Ret receptor tyrosine kinase. Nature 381, 789-793.
9. Gash D. M., Zhang Z., Ovadia A., Cass W. A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P. A., Collins F. C., Hoffer B. J. and Gerhardt G. A. (1996) Functional recovery in GDNF-treated parkinsonian monkeys. Nature 380, 252-255.
10. Heimer L., Zahm D. S. and Alheid G. F. (1995) Basal Ganglia. In The Rat Nervous System (ed. Paxinos G.), pp. 579-628, Academic Press Inc., San Diego.
11. Hoffer B. J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L.-F. and Gerhardt G. (1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons, in vivo. Neurosci. Lett. 182, 107-111.
12. Jakab R. L. and Leranth C. (1995) Septum. In The Rat Nervous System (ed. Paxinos G.), pp. 579-628, Academic Press Inc., San Diego.
13. Jing S., Wen D., Yu Y., Holst P. L., Luo Y., Fang M., Tamir R., Antonio L., Hu Z., Cupples R., Louis J. C., Hu S., Altrock B. and Fox G. M. (1996) GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell 85, 1113-1124.
14. Kearns C. and Gash D. M. (1995) GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672, 104-111.
15. Lapchak P. A., Araujo D. M. and Hefti F. (1993) Regulation of hippocampal muscarinic receptor function by chronic nerve growth factor treatment in adult rats with fimbrial transections. Neuroscience 53, 379-394.
16. Lapchak P. A., Beck K. D., Araujo D. M., Irwin I., Langston J. W. and Hefti F. (1993) Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection. Neuroscience 53, 639-650.
17. Lapchak P. A., Jiao S., Miller P. J., Williams L. R., Cummins V., Inouye G., Matheson C. R. and Yan Q. (1996) Pharmacological characterization of glial cell line-derived neurotrophic factor (GDNF): implications for GDNF as a therapeutic molecule for treating neurodegenerative diseases. Cell Tiss. Res. 286, 179-189.
18. Lapchak P. A., Miller P. J., Collins F. and Jiao S. (1997) Glial cell line-derived neurotrophic factor attenuates behavioral deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience 78, 61-72.
19. Lapchak P. A., Miller P. J., Jiao S., Araujo D. M., Hilt D. and Collins F. (1996) Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease. Neurodegeneration 5, 197-205.
20. Martin D., Miller G., Rosendahl M. and Russell D. A. (1995) Potent inhibitory effects of GDNF against kainic acid mediated seizures in rats. Brain Res. 683, 172-178.
21. Martin J. B. and Beal M. F. (1992) Huntington's disease and neurotoxins. Ann. N. Y. Acad. Sci. 648, 169-175.
22. Moore M. W., Klein R. D., Farinas I., Sauer H., Armanini M., Phillips H., Reichardt L. F., Ryan A. M., Carver-Moore K. and Rosenthal A. (1996) Renal and neuronal abnormalities in mice lacking GDNF. Nature 382, 76-79.
23. Pachnis V., Mankoo B. and Costantini F. (1993) Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 119, 1005-1017.
24. Perez-Navarro E., Arenas E., Reiriz J., Calvo N. and Alberch J. (1996) Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage. Neuroscience 75, 345-352.
25. Pichel J. G., Shen L., Sheng H. Z., Granholm A. C., Drago J., Grinberg A., Lee E. J., Huang S. P., Saarma M., Hoffer B. J., Sariola H. and Westphal H. (1996) Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382, 73-76.
26. Sanchez M. P., Silos-Santiago I., Frisen J., He B., Lira S. A. and Barbacid M. (1996) Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 382, 70-73.
27. Sauer H., Rosenblad C. and Bjorklund A. (1995) Glial cell line-derived neurotrophic factor but not transforming growth factor β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. natn. Acad. Sci. U.S.A. 92, 8935-8939.
28. Schuchardt A., D'Agati V., Larsson-Blomberg L., Costantini F. and Pachinis V. (1994) Defects in the kidney and enteric nervous system of mice lacking the tyrosine receptor ret. Nature 367, 380-383.
29. Sharp A. H. and Ross C. A. (1996) Neurobiology of Huntington's disease. Neurobiol. Disease 3, 3-15.
30. 3H]tiagabine (NNC 05-328) to the GABA uptake carrier. Brain Res. 647, 231-241.
31. Tahira T., Ishizaka Y., Sugimura T. and Nagao M. (1988) Expression of proto-ret mRNA in embryonic and adult rat tissues. Biochem. biophys. Res. Commun. 153, 1290-1295.
32. Tomac A., Lindqvist E., Lin L.-F. H., Ogren S. O., Young D., Hoffer B. J. and Olson L. (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373, 335-339.
33. Treanor J. S., Goodman L., de Sauvage F., Stone D. M., Poulsen K. T., Beck C. D., Gray C., Armanini M. P., Pollock R. A., Hefti F., Phillips H. S., Goddard A., Moore M. W., Buj-Bello A., Davies A. M., Asai N., Takahashi M., Vandlen R., Henderson C. E. and Rosenthal A. (1996) Characterization of a multicomponent receptor for GDNF. Nature 382, 80-83.
34. Trupp M., Arenas A., Fainzilber M., Nilsson A. S., Sieber B. A., Grigoriou M., Kilkenny C., Salazar-Grueso E., Pachnis V., Arumae U., Sariola H., Saarma M. and Ibanez C. F. (1996) Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 381, 785-789.
35. Tsuzuki T., Takahashi M., Asai N., Iwashita T., Matsuyama M. and Asai J. (1995) Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene 10, 191-198.
36. Williams L. R., Inouye G., Cummins V. and Pelleymounter M. A. (1996) Glial cell line-derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: dose-response comparison to nerve growth factor and brain-derived neurotrophic factor. J. Pharmac. exp. Ther. 277, 1140-1151.